Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del

Effect of CFTR modulator therapy on cystic fibrosis-related diabetes

(2021) Holly Gaines et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

(2021) Pierre-Régis Burgel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

(2021) Patrick A Flume et al.   Lancet Respiratory Medicine

Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease

(2021) Bermingham B et al.   Journal of Cystic Fibrosis

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial

(2021) Sivagurunathan Sutharsan et al.   Lancet Respiratory Medicine

MS1 VALIDATION OF MODELED 5-YEAR SURVIVAL OUTCOMES AMONG PATIENTS WITH CYSTIC FIBROSIS (CF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) IVACAFTOR USING US CF FOUNDATION PATIENT REGISTRY (USCFFPR) DATA

(2020) L. Mcgarry et al.   VALUE IN HEALTH

Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis

(2020) Sanja Stanojevic et al.   Journal of Cystic Fibrosis

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

(2019) Nataliya Volkova et al.   Journal of Cystic Fibrosis

WS12-3 Real-world outcomes among patients with cystic fibrosis treated with lumacaftor/ivacaftor (LUM/IVA) in 2017: an interim analysis of data from the US CF Foundation Patient Registry (CFFPR)

(2019) C. Knox et al.   Journal of Cystic Fibrosis

The future of cystic fibrosis care: a global perspective

(2019) Scott C Bell et al.   Lancet Respiratory Medicine

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

(2019) Harry G M Heijerman et al.   LANCET

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis

(2018) Christine Rousset-Jablonski et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations

(2018) Denis Hadjiliadis et al.   GASTROENTEROLOGY

Triplet CFTR modulators: future prospects for treatment of cystic fibrosis

(2018) Nauman Chaudary   Therapeutics and Clinical Risk Management

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

(2017) Jennifer L. Taylor-Cousar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

(2017) Michael W Konstan et al.   Lancet Respiratory Medicine

Cystic fibrosis: a clinical view

(2016) Carlo Castellani et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

(2016) Donald R. VanDevanter et al.   Journal of Cystic Fibrosis

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

(2015) Gregory S. Sawicki et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

(2015) Claire E. Wainwright et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis

(2014) Penny Whiting et al.   HEALTH TECHNOLOGY ASSESSMENT

Cystic fibrosis

(2009) Brian P O'Sullivan et al.   LANCET